Skip to main content

Rheumatoid Arthritis

      RT @Janetbirdope: Which Adalimumab biosimilar to use (if any)? The race is on to have 1st Ada or 2nd reimbursed/preferen
      4 years ago

      Which Adalimumab biosimilar to use (if any)? The race is on to have 1st Ada or 2nd reimbursed/preferentially listed in US reimbursement plans & dare I say it mandatory switching like in Europe. Abstr#0798 #ACR2020 compares Abrilada & Humira in RA @RheumNow @CRASCRRheum https://t.co/AUcVZnc6Gj

      An International Panel Weighs in on RA Studies from Day 1 at ACR

      Dr. Jonathan Kay leads a panel of rheumatologists from Dublin, Australia, The Philippines, Boston and Baltimore to talk about several initial abstracts that caught their attention at ACR 2020. Panel participants: Dr. Richard Conway, Dr. David Liew, Dr. Sheila Reyes, Dr. Jeffrey Sparks and Dr. Eric Dein.

      RT @RHEUMarampa: What is your initial csDMARD of choice in pts w/ elderly-onset RA? @RheumNow #ACR20
      4 years ago
      What is your initial csDMARD of choice in pts w/ elderly-onset RA? @RheumNow #ACR20
      RT @ejdein1: Serial RF titers? Abst#0754 from Japan: Pts with RF>45, tracked RF at month 0/4/12 after starting b/tsDM
      4 years ago
      Serial RF titers? Abst#0754 from Japan: Pts with RF>45, tracked RF at month 0/4/12 after starting b/tsDMARD. 46/130 had RF decrease titers, had better radiographic remission/DAS28-ESR. Limits: varied Rx, More aggressive Rx w RF decrease grp @RheumNow. #ACR20
      RT @ejdein1: #ACR20 @RheumNow. We think of dichotomy of erosive vs. non-erosive but Abst#0748 shows joint space narrowin
      4 years ago
      #ACR20 @RheumNow. We think of dichotomy of erosive vs. non-erosive but Abst#0748 shows joint space narrowing precedes erosive disease and requires more attention for early recognition. https://t.co/JLd3xVTlXM
      HCQ and QTc Prolongation: Dr David Liew

      Dr. David Liew reviews abstracts #0431 presented at the ACR 2020 annual meeting - and shares the results of the Twitter poll he conducted asking when prescribing HCQ, is an EKG routinely ordered either before or doing.  

      RT @ejdein1: Will we start getting fine-specificity ACPAs to drive treatment of RA? Abst#0743 shows fs-ACPA (anti-fibrin
      4 years ago
      Will we start getting fine-specificity ACPAs to drive treatment of RA? Abst#0743 shows fs-ACPA (anti-fibrinogen B) predict greater response to ABA+MTX vs MTX alone. #ACR20 @RheumNow. Role of RA antibodies will continue to evolve and guide Rx. https://t.co/pY4mm19Jc7
      RT @MeralElRamahiMD: What do you think? The great debate continues... leave your thoughts in the comment section below!
      What do you think? The great debate continues... leave your thoughts in the comment section below! #ACR20 @RheumNow @LCalabreseDO @CCalabreseDO https://t.co/KwQX0XoO93
      What to do with Subclinical Synovitis? Dr. Jack Cush

      Dr. Jack Cush discusses abstract #0481 presented Friday at the ACR 2020 annual meeting. 

      Safety of JAKs: Venous Thromboembolic Risk: Dr. Kevin Winthrop

       

      OHSU rheumatologist Dr. Kevin Winthrop in Portland looks at two posters -- abstracts #0215 and #0229 presented Friday at ACR 2020.